Access the full text.
Sign up today, get DeepDyve free for 14 days.
Loading next page...
/lp/springer_journal/positive-effectiveness-of-tafamidis-in-delaying-disease-progression-in-k96f6KWL40
References (50)
-
V. Planté-Bordeneuve (2014)
Update in the diagnosis and management of transthyretin familial amyloid polyneuropathyJournal of Neurology, 261
-
Vyndaqel Ò Summary of Product Characteristics -
C. Nduka, S. Stranges, G. Bloomfield, P. Kimani, G. Achinge, A. Malu, O. Uthman (2016)
A plausible causal link between antiretroviral therapy and increased blood pressure in a sub-Saharan African setting: A propensity score-matched analysis.International journal of cardiology, 220
-
P. Rosenbaum, D. Rubin (1985)
Constructing a Control Group Using Multivariate Matched Sampling Methods That Incorporate the Propensity ScoreThe American Statistician, 39
-
T. Coelho, L. Maia, A. Silva, M. Cruz, V. Planté-Bordeneuve, P. Lozeron, O. Suhr, J. Campistol, I. Conceição, H. Schmidt, P. Trigo, J. Kelly, R. Labaudinière, Jason Chan, J. Packman, Amy Wilson, D. Grogan (2012)
Tafamidis for transthyretin familial amyloid polyneuropathyNeurology, 79
-
A. Cortese, G. Vita, M. Luigetti, M. Russo, G. Bisogni, M. Sabatelli, F. Manganelli, L. Santoro, T. Cavallaro, G. Fabrizi, A. Schenone, M. Grandis, C. Gemelli, A. Mauro, L. Pradotto, L. Gentile, C. Stancanelli, C. Stancanelli, A. Lozza, S. Perlini, G. Piscosquito, D. Calabrese, A. Mazzeo, L. Obici, D. Pareyson (2016)
Monitoring effectiveness and safety of Tafamidis in transthyretin amyloidosis in Italy: a longitudinal multicenter study in a non-endemic areaJournal of Neurology, 263
-
C. Lim, A. Doussot, Michael Osseis, C. Salloum, Concepción Gavara, P. Compagnon, F. Brunetti, J. Calderaro, D. Azoulay (2016)
Primary Tumor Versus Liver-First Strategy in Patients with Stage IVA Colorectal Cancer: A Propensity Score Analysis of Long-term Outcomes and Recurrence PatternAnnals of Surgical Oncology, 23
-
V. Planté-Bordeneuve, T. Lalu, M. Misrahi, M. Reilly, D. Adams, C. Lacroix, G. Said (1998)
Genotypic-phenotypic variations in a series of 65 patients with familial amyloid polyneuropathyNeurology, 51
-
P. Lozeron, M. Théaudin, Z. Mincheva, Béatrice Ducot, Catherine Lacroix, David Adams (2013)
Effect on disability and safety of Tafamidis in late onset of Met30 transthyretin familial amyloid polyneuropathyEuropean Journal of Neurology, 20
-
D. Rowczenio, Islam Noor, J. Gillmore, H. Lachmann, C. Whelan, P. Hawkins, L. Obici, P. Westermark, G. Grateau, A. Wechalekar (2014)
Online Registry for Mutations in Hereditary Amyloidosis Including Nomenclature RecommendationsHuman Mutation, 35
-
D. Adams, C. Cauquil, C. Labeyrie (2017)
Familial amyloid polyneuropathyCurrent Opinion in Neurology, 30
-
B. Ericzon, H. Wilczek, M. Larsson, Priyantha Wijayatunga, A. Stangou, J. Pena, E. Furtado, E. Barroso, J. Daniel, D. Samuel, R. Adam, V. Karam, J. Poterucha, D. Lewis, B. Ferraz-Neto, M. Cruz, M. Munar-Qués, J. Fabregat, S. Ikeda, Y. Ando, N. Heaton, G. Otto, O. Suhr (2015)
Liver Transplantation for Hereditary Transthyretin Amyloidosis: After 20 Years Still the Best Therapeutic Alternative?Transplantation, 99
-
T Coelho, M Inês, I Conceição, P Saramago, M Carvalho, J Costa (2016)
Long-term survival of 3000 transthyretin familial amyloid polyneuropathy patients over a centuryInt J Clin Neurosci Mental Health., 3
-
T. Coelho, M. Maurer, O. Suhr (2013)
THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosisCurrent Medical Research and Opinion, 29
-
L. Mariani, P. Lozeron, M. Théaudin, Z. Mincheva, A. Signaté, B. Ducot, V. Algalarrondo, C. Denier, C. Adam, G. Nicolas, D. Samuel, M. Slama, C. Lacroix, M. Misrahi, D. Adams (2015)
Genotype–phenotype correlation and course of transthyretin familial amyloid polyneuropathies in FranceAnnals of Neurology, 78
-
B. Freedman, G. Lip (2016)
“Unreal world” or “real world” data in oral anticoagulant treatment of atrial fibrillationThrombosis and Haemostasis, 116
-
E. Vinik, A. Vinik, J. Paulson, I. Merkies, J. Packman, D. Grogan, T. Coelho (2014)
Norfolk QOL‐DN: validation of a patient reported outcome measure in transthyretin familial amyloid polyneuropathyJournal of the Peripheral Nervous System, 19
-
Tomoki Wada, H. Yasunaga, H. Horiguchi, K. Fushimi, Takehiro Matsubara, Susumu Nakajima, N. Yahagi (2016)
Ozagrel for Patients With Noncardioembolic Ischemic Stroke: A Propensity Score-Matched Analysis.Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association, 25 12
-
T. Coelho, A. Vinik, E. Vinik, T. Tripp, J. Packman, D. Grogan (2017)
Clinical measures in transthyretin familial amyloid polyneuropathyMuscle & Nerve, 55
-
G. Merlini, V. Planté-Bordeneuve, D. Judge, H. Schmidt, L. Obici, S. Perlini, J. Packman, T. Tripp, D. Grogan (2013)
Effects of Tafamidis on Transthyretin Stabilization and Clinical Outcomes in Patients with Non-Val30Met Transthyretin AmyloidosisJournal of Cardiovascular Translational Research, 6
-
Rajeev Dehejia, S. Wahba (2002)
Propensity Score-Matching Methods for Nonexperimental Causal StudiesReview of Economics and Statistics, 84
-
V Plante-Bordeneuve, G Said (2011)
Familial amyloid polyneuropathyLancet Neurol, 10
-
F. Tian, X. Hong, Wenming Wu, Xianlin Han, M-Y Wang, L. Cong, Menghua Dai, Quan Liao, Taiping Zhang, Yupei Zhao (2016)
Propensity score‐matched analysis of robotic versus open surgical enucleation for small pancreatic neuroendocrine tumoursBritish Journal of Surgery, 103
-
Y. Ando, Y. Sekijima, K. Obayashi, T. Yamashita, M. Ueda, Y. Misumi, H. Morita, K. Machii, M. Ohta, A. Takata, S. Ikeda (2016)
Effects of tafamidis treatment on transthyretin (TTR) stabilization, efficacy, and safety in Japanese patients with familial amyloid polyneuropathy (TTR-FAP) with Val30Met and non-Val30Met: A phase III, open-label studyJournal of the Neurological Sciences, 362
-
Jaebong Lee, Y. Ko, Soyeon Ahn, Ji Park, Hwa Kim, Seung-sik Hwang, Kyoung-Ho Lee (2016)
Comparison of US and CT on the effect on negative appendectomy and appendiceal perforation in adolescents and adults: A post‐hoc analysis using propensity‐score methodsJournal of Clinical Ultrasound, 44
-
M. Cruz, L. Amass, D. Keohane, J. Schwartz, Huihua Li, B. Gundapaneni (2016)
Early intervention with tafamidis provides long-term (5.5-year) delay of neurologic progression in transthyretin hereditary amyloid polyneuropathyAmyloid, 23
-
E. Martens, W. Pestman, A. Boer, S. Belitser, O. Klungel (2008)
Systematic differences in treatment effect estimates between propensity score methods and logistic regression.International journal of epidemiology, 37 5
-
P Coutinho, SA Martins, LJ Lopes, BA Resende (1980)
Amyloid and Amyloidosis -
P. Coutinho, A. Silva, J. Lopes, P. Resende, A. Silva, L. Resende, A. Silva, J. Filho, A. Barbosa (1980)
Forty years of experience with type I amyloid neuropathy. Review of 483 cases -
T. Coelho, G. Merlini, C. Bulawa, J. Fleming, D. Judge, J. Kelly, M. Maurer, V. Planté-Bordeneuve, R. Labaudinière, R. Mundayat, S. Riley, I. Lombardo, P. Huertas (2016)
Mechanism of Action and Clinical Application of Tafamidis in Hereditary Transthyretin AmyloidosisNeurology and Therapy, 5
-
P. Rosenbaum, Donald Rubin (1983)
The central role of the propensity score in observational studies for causal effectsBiometrika, 70
-
V. Planté-Bordeneuve, F. Gorram, H. Salhi, T. Nordine, S. Ayache, P. Corvoisier, D. Azoulay, C. Féray, T. Damy, J. Lefaucheur (2017)
Long-term treatment of transthyretin familial amyloid polyneuropathy with tafamidis: a clinical and neurophysiological studyJournal of Neurology, 264
-
P. Austin (2008)
A critical appraisal of propensity‐score matching in the medical literature between 1996 and 2003Statistics in Medicine, 27
-
T. Coelho, L. Maia, A. Silva, M. Cruz, V. Planté-Bordeneuve, O. Suhr, I. Conceição, H. Schmidt, P. Trigo, J. Kelly, R. Labaudinière, Jason Chan, J. Packman, D. Grogan (2013)
Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathyJournal of Neurology, 260
-
Mohammad Saadeh (2016)
LiverLaboratory Investigation, 96
-
B. Gundapaneni, M. Sultan, D. Keohane, J. Schwartz (2017)
Tafamidis delays neurological progression comparably across Val30Met and non‐Val30Met genotypes in transthyretin familial amyloid polyneuropathyEuropean Journal of Neurology, 25
-
G. Grabowski, K. Kacena, J. Cole, C. Hollak, Lin Zhang, J. Yee, P. Mistry, A. Zimran, J. Charrow, Stephan Dahl (2009)
Dose-response relationships for enzyme replacement therapy with imiglucerase/alglucerase in patients with Gaucher disease type 1Genetics in Medicine, 11
-
M. Benson, J. Kincaid (2007)
The molecular biology and clinical features of amyloid neuropathyMuscle & Nerve, 36
-
O. Suhr, M. Larsson, B. Ericzon, H. Wilczek (2016)
Survival After Transplantation in Patients With Mutations Other Than Val30Met: Extracts From the FAP World Transplant RegistryTransplantation, 100
-
Tingting Li, Xiaobin Fu, L. Xiao, L. Su, Yaqing Dai, Qiwei Yao, Jiancheng Li (2019)
A propensity score-matched analysis -
T Coelho, LF Maia, A Martins da Silva (2012)
Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trialNeurology, 79
-
D. Jacobson, G. Gallo, J. Buxbaum (1998)
The systemic amyloidoses.The New England journal of medicine, 338 4
-
Y. Ando, T. Coelho, J. Berk, M. Cruz, B. Ericzon, S. Ikeda, D. Lewis, L. Obici, V. Planté-Bordeneuve, C. Rapezzi, G. Said, F. Salvi (2013)
Guideline of transthyretin-related hereditary amyloidosis for cliniciansOrphanet Journal of Rare Diseases, 8
-
D. Adams, O. Suhr, E. Hund, L. Obici, I. Tournev, J. Campistol, M. Slama, B. Hazenberg, T. Coelho (2016)
First European consensus for diagnosis, management, and treatment of transthyretin familial amyloid polyneuropathyCurrent Opinion in Neurology, 29
-
J. Gagne, Lauren Thompson, K. O'Keefe, A. Kesselheim (2014)
Innovative research methods for studying treatments for rare diseases: methodological reviewThe BMJ, 349
-
G. Lip, A. Keshishian, S. Kamble, Xianying Pan, J. Mardekian, R. Horblyuk, M. Hamilton (2016)
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarinThrombosis and Haemostasis, 116
-
GY Lip, A Keshishian, S Kamble (2016)
Real-world comparison of major bleeding risk among non-valvular atrial fibrillation patients initiated on apixaban, dabigatran, rivaroxaban, or warfarin. A propensity score matched analysisThromb Haemost, 116
-
(Pfizer Ltd. Vyndaqel® Summary of Product Characteristics. Sandwich, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf. Accessed: March 10, 2017.)
Pfizer Ltd. Vyndaqel® Summary of Product Characteristics. Sandwich, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf. Accessed: March 10, 2017.Pfizer Ltd. Vyndaqel® Summary of Product Characteristics. Sandwich, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf. Accessed: March 10, 2017., Pfizer Ltd. Vyndaqel® Summary of Product Characteristics. Sandwich, UK. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002294/WC500117862.pdf. Accessed: March 10, 2017.
-
V. Planté-Bordeneuve, O. Suhr, M. Maurer, Barbara White, D. Grogan, T. Coelho (2013)
The Transthyretin Amyloidosis Outcomes Survey (THAOS) registry: design and methodologyCurrent Medical Research and Opinion, 29
-
L. Connors, A. Lim, T. Prokaeva, Violet Roskens, C. Costello (2003)
Tabulation of human transthyretin (TTR) variants, 2003Amyloid, 10
- Publisher
- Springer Journals
- Copyright
- Copyright © 2018 by The Author(s)
- Subject
- Medicine & Public Health; Internal Medicine; Neurology
- ISSN
- 2193-8253
- eISSN
- 2193-6536
- DOI
- 10.1007/s40120-018-0097-9
- Publisher site
- See Article on Publisher Site
Abstract
Neurol Ther (2018) 7:87–101 https://doi.org/10.1007/s40120-018-0097-9 ORIGINAL RESEARCH Positive Effectiveness of Tafamidis in Delaying Disease Progression in Transthyretin Familial Amyloid Polyneuropathy up to 2 Years: An Analysis from the Transthyretin Amyloidosis Outcomes Survey (THAOS) . . . . Rajiv Mundayat Michelle Stewart Jose Alvir Sarah Short . . . Moh-Lim Ong Denis Keohane Denise Rill Marla B. Sultan Received: November 29, 2017 / Published online: April 9, 2018 The Author(s) 2018 Limbs (p \ 0.001) and its subscales (p \ 0.023) ABSTRACT compared with untreated subjects. There was significantly less deterioration among tafamidis- Introduction: The effectiveness of tafamidis for treated subjects compared with untreated sub- the treatment of transthyretin familial amyloid jects on the Norfolk Quality of Life scale polyneuropathy (TTR-FAP) was evaluated using (p \ 0.001). There were no significant differences data from the Transthyretin Amyloidosis Out- observed in functional (assessed by Karnofsky comes Survey (THAOS) registry. Performance Status Scale score) or nutritional Methods: Subjects receiving tafamidis (n = 252) (assessed by modified body mass index) status were compared with untreated subjects in a between the treated and untreated groups. The non-randomized, matched cohort analysis. primary model which examined survival from Subjects were matched with up to four baseline
Journal
Neurology and Therapy – Springer Journals
Published: Apr 9, 2018